Sudarshan Pharma Share Price Reverses From Rs 39 to Rs 36.42 on 30 October 2026 as Profit Booking Follows 86% Profit Jump in Sudarshan Pharma Q2 Results: Will the Small-Cap Pharma Stock Rebound?

Sudarshan Pharma share price Rs 36.42 (30 Oct close), down 2.83%. Opened up 5.5%, low Rs 34.70. Q2 PAT Rs 7.78 crore, up 86%. Up 30% plus YTD. NSE main board listed.

The Sudarshan Pharma share price did something on 30 October 2026 that small-cap investors know well: it opened 5.5% higher at Rs 39.04 on strong Sudarshan Pharma Q2 results, hit Rs 39.29, and then reversed into a 2.83% loss at Rs 36.42 as profit booking overwhelmed the buyers. The intraday swing in the Sudarshan Pharma stock from high to low was more than 11%, and it touched Rs 34.70 before recovering into the close.

This article looks at what the Sudarshan Pharma Q2 results showed, why the Sudarshan Pharma share price reversed despite an 86% jump in net profit, the strategic moves the company announced alongside the results, where the Sudarshan Pharma stock stands after a 30% plus year-to-date gain, and the levels that will decide whether a rebound follows the profit booking.

Click Here – Get Free Investment Predictions

Sudarshan Pharma Share Price Today: Key Data on 30 October 2026

The Sudarshan Pharma share price opened at Rs 39.04 on the NSE against a previous close of Rs 37.48, rose to Rs 39.29 in the first minutes, and then fell to Rs 34.70 before closing at Rs 36.42, down Rs 1.06 or 2.83%. Volume in the Sudarshan Pharma stock on the NSE was 1.84 lakh shares, and on the BSE, where it has traded for longer, 34,741 shares changed hands with a close of Rs 36.57. The Sudarshan Pharma stock listed on the NSE main board only on 27 October 2026, so NSE volumes are still building.

Metric	Value (30 October 2026)
NSE symbol	SUDARSHAN
Sudarshan Pharma share price (close)	Rs 36.42 (down 2.83%)
Day's range	Rs 34.70 to Rs 39.29
Opening price	Rs 39.04 (up 5.5% at the open)
Previous close	Rs 37.48
Year-to-date return	More than 30% (about 46% at the recent peak)
3-year return	About 369%
Market capitalisation	Rs 940 crore
P/E ratio (TTM)	37.70
Industry P/E	33.13
P/B ratio	5.63
Debt to equity	1.84
ROE	15.03%

Source: NSE, BSE and exchange data. Prices are as of the close on 30 October 2026. Year-to-date and three-year returns are from BSE analytics and data providers.

Sudarshan Pharma Q2 Results: Net Profit Up 86%, Revenue Up 28%

The Sudarshan Pharma Q2 results for the quarter ended 30 September 2026, announced on 29 October, showed consolidated net profit of Rs 7.78 crore, up 86% from Rs 4.18 crore in Q2 FY26. Revenue rose 28% year on year, adding about Rs 48.10 crore of quarterly sales, and grew 23.1% sequentially from the June quarter. The net profit margin expanded to 3.6% from 2.5% a year earlier, which means profit in the Sudarshan Pharma Q2 results grew more than three times faster than revenue, a sign of operating leverage in a business that still runs on thin margins.

Sudarshan Pharma Q2 results metric	Q2 FY27	Q2 FY26	Change
Net profit	Rs 7.78 crore	Rs 4.18 crore	Up 86% YoY
Revenue growth	Up 28% YoY		Up 23.1% QoQ
Incremental revenue vs Q2 FY26	About Rs 48.10 crore
Net profit margin	3.6%	2.5%	Up 110 bps
Trailing 12-month profit growth	Up 101%
Trailing 12-month revenue growth	Up 28%

Source: Sudarshan Pharma Industries Q2 FY27 exchange filing dated 29 October 2026 and exchange data. Over the last five quarters the company’s net profit has ranged from Rs 4.18 crore to Rs 10.73 crore, so the Sudarshan Pharma Q2 results are a solid but not record quarter.

Strategic Moves Announced With the Results

Three announcements came with the Sudarshan Pharma Q2 results. First, the board met on 29 October to consider raising funds through equity, convertible securities, warrants or debt, a fundraising that could dilute existing holders but would cut the company’s debt to equity ratio of 1.84. Second, the Sudarshan Pharma stock story now includes a US expansion through a 9.5% stake in MedTherapy Biotech, aimed at entering the American market. Third, it is closing its underperforming Palghar manufacturing unit, which management expects to reduce fixed costs and improve margins.

The NSE Main Board Migration

The Sudarshan Pharma stock listed on the BSE SME platform on 22 March 2023 and migrated to the NSE main board on 27 October 2026, three days before the results. Main board listing widens the investor base, allows institutional participation and removes the SME lot-size restrictions, which is one reason the Sudarshan Pharma stock jumped 9% on 28 October ahead of the Sudarshan Pharma Q2 results. It also means the Sudarshan Pharma share price will now be judged by main board standards on disclosure, liquidity and governance.

Check the Univest Screener for live Sudarshan Pharma stock data

Why Did Sudarshan Pharma Share Price Fall After Strong Q2 Results?

The Sudarshan Pharma share price fell after strong Q2 results because the Sudarshan Pharma stock had already run up 9% on 28 October and more than 30% for the year, so traders who bought ahead of the numbers used the 5.5% gap-up opening to book profits. In a small-cap with a market value of Rs 940 crore and thin NSE volumes of under 2 lakh shares, that selling is enough to reverse the Sudarshan Pharma share price by 11% from high to low. The pending fundraising also weighs, because investors do not yet know the price or the instrument, and any issue below the market price would dilute them.

There is also a valuation argument against the Sudarshan Pharma share price. At Rs 36.42 the Sudarshan Pharma stock trades at 37.7 times trailing earnings against an industry P/E of 33, at 5.6 times book value, and with a debt to equity of 1.84, which is high for a pharma company. An 86% profit jump on a small base of Rs 4.18 crore is impressive in percentage terms but adds only Rs 3.60 crore in absolute profit, and the market is now asking whether the margin improvement to 3.6% in the Sudarshan Pharma Q2 results can continue.

Sudarshan Pharma Stock: Up 30% YTD, Up 369% in 3 Years Before the Sudarshan Pharma Q2 results

The Sudarshan Pharma stock has risen more than 30% in 2026 and about 369% over three years, with BSE analytics showing a three-year return of 366.75% as of 28 October. The one-year return on the Sudarshan Pharma share price, however, is close to flat at about 1%, which means most of the three-year gain came in 2024 and early 2025, and the 2026 rally has recovered ground lost in late 2025. The Sudarshan Pharma stock has roughly tripled the Sensex over three years but is far more volatile, with 5% to 10% daily swings common.

Sudarshan Pharma stock return	Period	Comment
Year-to-date 2026	More than 30% (46% at peak)	Driven by Q2 results, NSE listing and US plans
1 year	About 1%	Flat, recovering 2025 losses
3 years	About 369%	SME listing in March 2023 at a low base
30 October 2026 session	Down 2.83%	Reversed from a 5.5% gap-up on profit booking

Source: BSE analytics and exchange data as of 30 October 2026.

Download the Univest iOS App or Univest Android App to track the Sudarshan Pharma share price live and get daily stock research.

Will Sudarshan Pharma Share Price Rebound After Profit Booking?

A rebound in the Sudarshan Pharma share price, and the credibility of the US expansion story, depends on two things: whether Friday’s low of Rs 34.70 holds as support, and whether the fundraising is priced at or near the market rather than at a steep discount. If both go the right way, the earnings momentum in the Sudarshan Pharma Q2 results, the US expansion through MedTherapy Biotech and the cost savings from the Palghar closure give the Sudarshan Pharma share price a path back above Rs 39, Friday’s high, and towards the 2026 peak around Rs 42. If the Sudarshan Pharma stock breaks below Rs 34.70 on volume, the profit booking would turn into a deeper correction, with Rs 32 to 33 as the next support.

Investors in the Sudarshan Pharma share price should also remember what a small-cap pharma and speciality chemicals company with a 3.6% net margin is: a business where a single large order or one bad quarter can swing profit by 50%. The 86% growth in the Sudarshan Pharma Q2 results is real, but the five-quarter profit range of Rs 4.18 crore to Rs 10.73 crore shows how lumpy it is, and the Sudarshan Pharma share price will swing with each print.

Should You Buy Sudarshan Pharma Shares After the Q2 Results?

Buying the Sudarshan Pharma stock after the Sudarshan Pharma Q2 results is a high-risk, high-volatility decision suited only to investors comfortable with small-cap swings and with the uncertainty of a pending fundraising. Existing holders who bought earlier in 2026 can consider holding with a stop loss below Rs 34.70, since the Sudarshan Pharma Q2 results show the business growing and the NSE main board listing improves liquidity. New buyers may prefer to wait for the fundraise terms to be announced, because the price and instrument will decide how much dilution comes with the growth. This is not investment advice; consult a SEBI-registered financial advisor before trading a small-cap stock.

Subscribe to Univest Pro for premium small-cap research

Conclusion

The Sudarshan Pharma share price at Rs 36.42 on 30 October 2026 tells two stories at once: a company whose Sudarshan Pharma Q2 results showed net profit up 86% and margins improving, and a small-cap stock that has run up more than 30% this year and gave back a 5.5% opening gain to profit booking within hours. The NSE main board listing, the US expansion plan and the Palghar closure are real positives for the Sudarshan Pharma share price, while the fundraising, the 1.84 debt to equity ratio and a 37.7 times P/E are the reasons for caution. The level to watch is Rs 34.70; hold it and a rebound towards Rs 39 is possible, lose it and the correction deepens.

Frequently Asked Questions on Sudarshan Pharma Share Price

What is the Sudarshan Pharma share price today, 30 October 2026?

Ans. Sudarshan Pharma share price closed at Rs 36.42 on the NSE on 30 October 2026, down Rs 1.06 or 2.83% from the previous close of Rs 37.48. The stock opened 5.5% higher at Rs 39.04, rose to Rs 39.29 and then fell to an intraday low of Rs 34.70 before recovering into the close. On the BSE the Sudarshan Pharma stock closed at Rs 36.57, and the Sudarshan Pharma share price values the company at about Rs 940 crore.

What were the Sudarshan Pharma Q2 results for FY27?

Ans. Sudarshan Pharma Q2 results for the quarter ended 30 September 2026 showed consolidated net profit of Rs 7.78 crore, up 86% from Rs 4.18 crore in Q2 FY26, and revenue growth of 28% year on year, which added about Rs 48.10 crore of quarterly sales. Revenue also grew 23.1% from the June quarter. The net profit margin expanded to 3.6% from 2.5% a year earlier. Alongside the results, the company announced a board meeting on fundraising, a 9.5% stake in MedTherapy Biotech for US market entry, and the closure of its Palghar manufacturing unit.

Why did Sudarshan Pharma share price fall despite strong Q2 results?

Ans. Sudarshan Pharma share price fell 2.83% on 30 October 2026 despite an 86% jump in Q2 profit because of profit booking after the stock had already risen 9% on 28 October and more than 30% in 2026. The Sudarshan Pharma share price opened 5.5% higher and then reversed as traders sold into the gap-up after the Sudarshan Pharma Q2 results. Uncertainty about the pending fundraising, which could dilute existing shareholders, and a valuation of 37.7 times trailing earnings with a debt to equity of 1.84 also contributed to the selling in the small-cap stock.

Will Sudarshan Pharma stock rebound after the profit booking?

Ans. Sudarshan Pharma stock can rebound if Friday's intraday low of Rs 34.70 holds as support and if the planned fundraising is priced close to the market rather than at a steep discount. The earnings growth in the Sudarshan Pharma Q2 results, the US expansion through MedTherapy Biotech, the Palghar unit closure and the NSE main board listing are supportive factors for the Sudarshan Pharma share price. A break below Rs 34.70 on volume would signal a deeper correction towards Rs 32 to 33. Small-cap stocks with thin volumes can swing 5% to 10% in a day, so investors should expect volatility.

How much has Sudarshan Pharma share price gained in 2026 and in 3 years?

Ans. Sudarshan Pharma share price has gained more than 30% year to date in 2026, with the gain reaching about 46% at the recent peak, and about 369% over three years, with BSE analytics showing a three-year return of 366.75% as of 28 October 2026. The one-year return is close to flat at about 1%, which means the 2026 rally has mostly recovered ground lost in late 2025. The Sudarshan Pharma stock listed on the BSE SME platform on 22 March 2023 and moved to the NSE main board on 27 October 2026.

What is Sudarshan Pharma's fundraising plan?

Ans. Sudarshan Pharma Industries' board met on 29 October 2026 to consider proposals for raising funds through the issue of equity shares, convertible securities, warrants or debt instruments. The exact amount, instrument and pricing had not been announced as of 30 October 2026, which is one reason the Sudarshan Pharma stock sold off after the Sudarshan Pharma Q2 results. The fundraise is expected to support the company's US expansion through its 9.5% stake in MedTherapy Biotech and to reduce leverage, since the company has a debt to equity ratio of 1.84, but it could dilute existing shareholders depending on the terms.

What does Sudarshan Pharma Industries do?

Ans. Sudarshan Pharma Industries is a Mumbai-based pharmaceutical and speciality chemicals company founded in 2008 and formerly known as Sudarshan Specialty Chemsolve. It manufactures and trades pharmaceutical formulations, active ingredients and speciality chemicals, with a trailing twelve-month revenue growth of 28% and profit growth of 101%. The Sudarshan Pharma stock listed on the BSE SME platform in March 2023, migrated to the NSE main board in October 2026, and is now pursuing US market entry through a stake in MedTherapy Biotech while closing its Palghar manufacturing unit to improve margins.

Is Sudarshan Pharma a good stock to buy now?

Ans. Sudarshan Pharma is a high-risk small-cap stock with a market capitalisation of about Rs 940 crore, a trailing P/E of 37.7 times, a debt to equity of 1.84 and a net margin of 3.6%, so it suits only investors comfortable with volatility. The Sudarshan Pharma Q2 results were strong, with profit up 86%, and the NSE main board listing and US plans are positives, but the pending fundraising could dilute shareholders and the Sudarshan Pharma share price reversed sharply on 30 October after profit booking. New buyers may prefer to wait for the fundraise terms. Consult a SEBI-registered financial advisor before buying.